RBC Capital Downgrades Immune Design (IMDZ) to Sector Perform Following Takeover Deal
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams downgraded Immune Design (NASDAQ: IMDZ) from Outperform to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
